Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of ($1.16), $0.09 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $4.83 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.